Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Dr Reddy’s Laboratories ( (RDY) ) is now available.
On March 21, 2025, Dr. Reddy’s Laboratories Inc., a wholly owned subsidiary of Dr. Reddy’s Laboratories Limited, completed the sale of its wholly owned subsidiary, Dr. Reddy’s Laboratories Louisiana LLC, including its manufacturing facility in Shreveport, Louisiana. This transaction marks the cessation of Dr. Reddy’s Laboratories Louisiana LLC as a subsidiary, potentially impacting the company’s operational focus and market strategy in the U.S. pharmaceutical manufacturing sector.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a prominent player in the pharmaceutical industry, primarily engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company focuses on providing affordable and innovative medicines, with a significant presence in both the generic and branded markets globally.
YTD Price Performance: -12.51%
Average Trading Volume: 1,866,582
Technical Sentiment Signal: Hold
Current Market Cap: $11.63B
For a thorough assessment of RDY stock, go to TipRanks’ Stock Analysis page.